Translational studies using preclinical PK/PD models

19:15 • 2997 • Combination treatments show potential to suppress the evolution of fluoroquinolone resistance in <em>Streptococcus pneumoniae</em> > L. Linda Brita Sofia AULIN (Leiden) 19:25 • 886 • Defining the toxicodynamic link between rats and humans for vancomycin-induced kidney injury > M. Marc SCHEETZ (Downers Grove) 19:35 • 950 • Prediction of minocycline activity in the gut from a pig preclinical model using a pharmacokinetic/pharmacodynamic approach > Q. Quentin VALLE (Toulouse) 19:45 • 2442 • Pharmacokinetics, tissue distribution and efficacy of VIO-001 formulation (meropenem/piperacillin/tazobactam) following intravenous administration for treatment of experimental methicillin-resistant <em>Staphylococcus aureus </em>(MRSA) vascular catheter-related bloodstream infections in immunocompetent rabbits > V. Vidmantas PETRAITIS (New York) 19:55 • 842 • Pharmacodynamics of fosfomycin and flomoxef combination therapy for neonatal sepsis modelled in a hollow-fibre infection model > C. Christopher DARLOW (Liverpool) 20:05 • 1846 • An integrated model of plasma and lung PK and <em>in vitro</em> and <em>in vivo</em> efficacy for translational evaluation of apramycin in <em>Pseudomonas aeruginosa</em> lung infection > V. Vincent ARANZANA-CLIMENT (Uppsala) 20:15 • 852 • Development of a translational modelling and simulation platform for flagellin PK/PD in the context of flagellin aerosol therapy as an immunomodulatory adjunct to the antibiotic treatment of drug-resistant bacterial pneumonia (FAIR) > R. Robin MICHELET (Berlin) 20:25 • INT82 • Q&A/Discussion